Mar 02, 2020 / 06:30PM GMT
Ryan Blicker - Cowen and Company, LLC, Research Division - VP of Healthcare
All right. Hi, everyone. Thank you for coming. We're very happy to have the full Insulet team with us here today. And I think we're going to start with some prepared remarks on some breaking news and then we'll jump into a fireside chat.
Shacey Petrovic - Insulet Corporation - President, CEO & Director
Yes, great. Thanks, Ryan. So it's great to be here with you. We've lots of exciting things going on at Insulet. And it's a good opportunity for me personally to address one particular update.
This morning, we announced that we are pausing the Horizon pivotal trial. For most -- anyone in the room who doesn't know what that is, Horizon is our automated insulin delivery system that's under investigation. And we are about halfway through the trial, so about 9,000 patient-wearing days in a total of 21,000 patient-wearing days that we expect news to submit to the FDA for clearance. And we learned just recently of a software anomaly that in certain circumstances relate to how the CGM
Insulet Corp at Cowen HealthCare Conference Transcript
Mar 03, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers